FIELD: medicine.
SUBSTANCE: inventions refers to medicine, namely to pulmonology, and can be used for treating a pulmonary disorder in a patient. That is ensured by administering an effective dose of the nebulised liposomal amikacin formulation of 100 to 2,500 mg daily within the cycle of treatment, which involves the period of administration from 15 to 75 days and the following withdrawal period from 15 to 75 days. The cycle of treatment repeats at least twice.
EFFECT: invention provides improving the pulmonary function, which is supported for at least 15 days after the termination of treatment, and increasing the one-second forced expiratory volume (FEV1).
28 cl, 16 tbl, 11 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING LEVOFLOXACIN IN AEROSOL FORM FOR TREATING MUCOVISCIDOSIS | 2010 |
|
RU2563809C2 |
| PROLONGED RELEASE OF ANTI-INFECTIOUS AGENTS | 2006 |
|
RU2438655C2 |
| ALPHA-1 PROTEINASE INHIBITOR FOR DELAY OF BEGINNING OR PROGRESS OF PULMONARY EXACERBATIONS | 2012 |
|
RU2635482C2 |
| INTRAPULMONARY ADMINISTRATION OF FUOROQUINOLONE | 2009 |
|
RU2497524C2 |
| METHODS OF TREATING ENDOBRONCHIAL DISEASES | 2005 |
|
RU2389477C2 |
| SYSTEMS FOR TREATMENT OF PULMONARY INFECTIONS | 2013 |
|
RU2657510C2 |
| METHODS OF TREATING PULMONARY BACTERIAL INFECTION WITH APPLICATION OF FLUOROQUINOLONES | 2010 |
|
RU2535056C2 |
| METHODS OF TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH USE OF BENRALIZUMAB | 2014 |
|
RU2706729C2 |
| STABLE COMPOSITIONS OF ASCORBIC ACID AND METHODS OF THEIR USE | 2018 |
|
RU2799046C2 |
| ALPHA-1-ANTITRYPSIN FOR TREATING EPISODES OF PULMONARY DISEASE AGGRAVATIONS | 2007 |
|
RU2472524C2 |
